Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Baxter
Dow
Boehringer Ingelheim
Merck

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

ADDERALL XR 10 Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Adderall Xr 10, and when can generic versions of Adderall Xr 10 launch?

Adderall Xr 10 is a drug marketed by Shire and is included in one NDA. There are four patents protecting this drug.

This drug has ten patent family members in eight countries.

The generic ingredient in ADDERALL XR 10 is amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate. There are fifty-five drug master file entries for this compound. Twenty-five suppliers are listed for this compound. Additional details are available on the amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate profile page.

Drug patent expirations by year for ADDERALL XR 10
Recent Clinical Trials for ADDERALL XR 10

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of WyomingPhase 2
United States Army Aeromedical Research LaboratoryPhase 2
Emory UniversityPhase 2

See all ADDERALL XR 10 clinical trials

Recent Litigation for ADDERALL XR 10

Identify potential future generic entrants

District Court Litigation
Case NameDate
Shire Development LLC v. Rhodes Pharmaceuticals L.P.2017-12-21
Shire Development LLC v. Teva Pharmaceuticals USA, Inc.2017-11-22
Shire LLC v. Abhai LLC2015-11-20

See all ADDERALL XR 10 litigation

PTAB Litigation
PetitionerDate
Mylan Pharmaceuticals Inc.2016-10-04
Mylan Pharmaceuticals Inc.2016-05-12
Amerigen Pharmaceuticals Limited2015-10-01

See all ADDERALL XR 10 litigation

Pharmacology for ADDERALL XR 10
Synonyms for ADDERALL XR 10
24 HR Amphetamine aspartate
ADDERALL 10
ADDERALL 12.5
ADDERALL 15
ADDERALL 20
ADDERALL 30
ADDERALL 5
ADDERALL 7.5
ADDERALL XR 15
ADDERALL XR 20
ADDERALL XR 25
ADDERALL XR 30
ADDERALL XR 5
Adzenys XR-ODT
Amphetamine aspartate mixture with amphetamine sulfate, dextroamphetamine saccharate and dextroamphetamine sulfate
Dextroamphetamine sulfate mixture with dextroamphetamine saccharate and amphetamine aspartate monohydrate and amphetamine sulfate
S900000010

US Patents and Regulatory Information for ADDERALL XR 10

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Shire ADDERALL XR 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-001 Oct 11, 2001 AB RX Yes No   Start Trial   Start Trial   Start Trial
Shire ADDERALL XR 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-001 Oct 11, 2001 AB RX Yes No   Start Trial   Start Trial   Start Trial
Shire ADDERALL XR 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-001 Oct 11, 2001 AB RX Yes No   Start Trial   Start Trial   Start Trial
Shire ADDERALL XR 10 amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate CAPSULE, EXTENDED RELEASE;ORAL 021303-001 Oct 11, 2001 AB RX Yes No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for ADDERALL XR 10

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Harvard Business School
McKesson
Moodys
Baxter
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.